Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling.

713 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Progress in tumor-associated macrophage (TAM)-targeted therapeutics (2017, positive): “Antibodies targeting CSF-1 or CSF-1R as well as CSF-1R kinase inhibitors have been developed for therapeutic modulation of resident macrophages and TAMs [66].”
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. (2014, background): “Colony-stimulating factor 1 (CSF-1) and its receptor, CSF-1R, regulate the migration, differentiation, and survival of macrophages and their precursors (Hume and MacDonald 2012; Chitu and Stanley 2006).”
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation (2014, background): “Experimentally blocking CSF-1R with antibodies leads to a reduction in Ly6C− monocytes (69) and to an associated increase in Ly6C+ monocytes, suggesting the involvement of CSF-1 in the maturation of monocytes from Ly6C+ to Ly6C− (48, 104).”
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications (2019, background): “In addition, tumor graft models showed that CSF-1 depletion led to greatly reduced macrophage density, delayed tumor progression, and severely inhibited metastasis [22, 24, 42, 43].”